SPECTRAL TO PRESENT AT RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE
ON SEPTEMBER 13

TORONTO, Sept. 13 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI), a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced that Dr. Paul Walker, the Company's President & Chief Executive Officer, will present at the Rodman & Renshaw Annual Investment Conference.

Dr. Walker will discuss Spectral's lead theranostics product that combines the EAA(TM) diagnostic with the Toraymyxin(TM) therapeutic, the initiation of its U.S. Phase III pivotal trial, the world's first theranostics trial in the area of sepsis, and the upcoming milestones for the Company. More than 250,000 patients are diagnosed with severe sepsis and septic shock in the U.S. each year, representing a greater than $1 billion market opportunity for Spectral.

WHEN: Monday September 13, 2010 at 4:55 pm (Eastern Time)

WHERE: The Winslow Salon, The Palace Hotel New York

An archived version of the power point will be available following the presentation at the Company's web site.

For additional information on the conference please visit http://www.rodmanandrenshaw.com/conferences?id=51.

About Spectral Diagnostics

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin(TM) is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA(TM)), the only FDA cleared diagnostic for the detection of endotoxin, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin(TM) has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively in more than 70,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin(TM). More than 250,000 patients are diagnosed with severe sepsis and septic shock in the U.S. each year, representing a greater than $1 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00002006E

For further information: Dr. Paul Walker, President & CEO, 416-626-3233 ext. 2100; Casey Gurfinkel, Investor Relations, 416-815-0700 ext. 283, [email protected]